Stockhub

BioVaxys Technology Corp.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

23 August 2022

  • curprev 07:4107:41, 23 August 2022 >Nick 1,057 bytes +1,057 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical..."
Retrieved from "https://stockhub.co/research/BioVaxys_Technology_Corp."